M&A - OnKure Therapeutics, Inc.

Form Type: POS AM

Filing Date: 2025-03-20

Corporate Action: Merger

Type: Update

Accession Number: 000119312525058954

Filing Summary: OnKure Therapeutics, Inc. filed a Post-Effective Amendment No. 1 to Form S-1 Registration Statement with the SEC on March 20, 2025. This amendment includes updates from the previously filed Registration Statement effective on October 30, 2024, particularly the financial statements for the fiscal year ending December 31, 2024. The document discusses the merger between Reneo Pharmaceuticals, Inc. (now OnKure) and Legacy OnKure, finalized on October 4, 2024. Key changes include a reverse stock split, the naming of the resulting entity as OnKure Therapeutics, and adjustments to outstanding common stock, stock options, and restricted stock units. The filing also mentions that no additional securities are being registered in this amendment, focusing instead on amending existing information from the original registration statement and regulatory compliance. Financial performance indicators and the completion of the business combination are central to this update, with ongoing discussions surrounding initial public offerings and market operations under the Nasdaq symbol OKUR.

Document Link: View Document

Form Type: 10-K

Filing Date: 2025-03-10

Corporate Action: Merger

Type: New

Accession Number: 000095017025036252

Filing Summary: OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company recently completed a merger transaction with Reneo Pharmaceuticals, transforming Reneo into OnKure. This merger included a reverse stock split and reclassification of common stock into Class A and Class B stocks. Following the merger, Legacy OnKure became a wholly-owned subsidiary of OnKure Therapeutics, Inc. The report highlights OnKure's commitment to advancing its lead product candidate, OKI-219, a selective inhibitor of the PI3Kα protein, specifically targeting the H1047R mutation associated with cancer. The document outlines OnKure's ongoing efforts in its clinical trials and the anticipated outcomes regarding patient selection and treatment efficacy, along with associated risks.

Document Link: View Document